Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy

Frontiers in Immunology

Immunology

Er-lei Zhang¹ 

[1] Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

关键词: hepatocellular carcinoma;    immunotherapy;    targeted therapy;    conversion therapy;    postoperative adjuvant therapy;   

DOI  :  10.3389/fimmu.2023.1218845

 received in 2023-05-08, accepted in 2023-05-15,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Zhang